R

Rallybio Corp
NASDAQ:RLYB

Watchlist Manager
Rallybio Corp
NASDAQ:RLYB
Watchlist
Price: 0.6789 USD -0.01% Market Closed
Market Cap: 28.7m USD

During the last 3 months Rallybio Corp insiders have not bought any shares, and have not sold any shares. The stock price has increased by 21% over this period (open performance analysis).

The last transaction was made on Mar 14, 2023 by Lieber Jonathan I , who bought 26.1k USD worth of RLYB shares.

Last Transactions:
Lieber Jonathan I
$+26.1k
Parmar Kush
$-820k
Rocklage Scott M
$-820k
Viking Global Investors Lp
$+20m
Parmar Kush
$-1.2m
Rocklage Scott M
$-629.1k
Parmar Kush
$-863.8k
Rocklage Scott M
$-436.2k
Fryer Jeffrey M
$+24.1k
Parmar Kush
$-1.8m
Rocklage Scott M
$-919.5k
Fryer Jeffrey M
$+12.2k
Uden Stephen
$+38k
Uden Stephen
$+52.8k
Mackay Martin
$+47.9k
Mackay Martin
$+55.6k
Fryer Jeffrey M
$+6.3k
Parmar Kush
$+8m
Hopfner Robert Lorne
$+7.5m
Hunt Ronald
$+2m
Rocklage Scott M
$+8m
Shannon Timothy M
$+1 000k
Viking Global Investors Lp
$+10.5m
View All Transactions

During the last 3 months Rallybio Corp insiders have not bought any shares, and have not sold any shares. The stock price has increased by 21% over this period (open performance analysis).

The last transaction was made on Mar 14, 2023 by Lieber Jonathan I , who bought 26.1k USD worth of RLYB shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Rallybio Corp
Insider Trading Chart

Rallybio Corp
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Rallybio Corp
Last Insider Transactions

Global
Insiders Monitor

Rallybio Corp
Glance View

Market Cap
28.5m USD
Industry
Biotechnology

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 35 full-time employees. The company went IPO on 2021-07-29. The firm is engaged in discovering, developing, manufacturing and delivering therapies that improve the lives of patients suffering from severe and rare diseases. The company offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. The company provides RLYB211, a polyclonal anti-HPA-1a antibody. Its RLYB211 is in Phase I/II clinical trial. The Company’s lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody. The company is also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and ophthalmic disorders. Its RLYB116 is a long-acting, subcutaneously administered inhibitor of complement factor 5 (C5) in development for the treatment of patients with PNH and gMG. The company also includes RLYB114, which is a pegylated C5 inhibitor.

RLYB Intrinsic Value
0.5083 USD
Overvaluation 25%
Intrinsic Value
Price
R

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top